Glycogen storage disease type IV
ICD-10 E74.0 · ICD-11 5C51.3.4

Treatment of Glycogen storage disease type IV in neurogenic bladder with urinary hesitancy and emptying difficulty

Patients with Glycogen storage disease type IV can develop neurogenic bladder, presenting with urinary hesitancy, straining to void, a slow or weak stream, and incomplete bladder emptying. Managing these voiding symptoms requires a structured, stepwise approach tailored to this population.

Clinical scenario
Neurogenic bladder Urinary hesitancy Urinary straining Slow urinary stream Urinary emptying difficulty

This protocol addresses GSD type IV patients with lower urinary tract dysfunction — difficulty initiating urination, a slow or reduced stream, and incomplete emptying — in the context of neurogenic bladder as part of the disease's systemic involvement.

Clinical goal

The primary target is improved urinary flow and emptying.

Treatment approach (partial overview)

First-line management centres on behavioural voiding strategies and neuromuscular techniques, including structured voiding schedules and pelvic floor exercises aimed at optimising relaxation and tone. Pharmacologic interventions may additionally be considered to support urinary flow.

The complete regimen, full sequencing, and pharmacologic specifics are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.1016/j.ymgme.2023.107525

For patients with hesitancy, straining, slow stream, or emptying difficulties, first-line treatments include timed voiding, double voiding (i.e., attempting to void again immediately after going), optimizing bowel function, and pelvic floor muscle exercises geared toward improving relaxation and tone (see Section 5.6).

Titrating muscle relaxants can be helpful in promoting pelvic floor relaxation during voiding.

α-blockers can be trialed to improve urinary flow and emptying, but there is limited data on efficacy, especially in women.

View source ↗